DLL3-EXPRESSING TUMORS
Clinical trials for DLL3-EXPRESSING TUMORS explained in plain language.
Never miss a new study
Get alerted when new DLL3-EXPRESSING TUMORS trials appear
Sign up with your email to follow new studies for DLL3-EXPRESSING TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare tumors: tarlatamab trial opens
Disease control Recruiting nowThis study tests the drug tarlatamab in people with advanced tumors that have a protein called DLL3. The goal is to see if the drug can shrink or control these tumors. About 29 adults with stage IV cancer will receive tarlatamab, and researchers will track how well it works and a…
Matched conditions: DLL3-EXPRESSING TUMORS
Phase: PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New scan could spot hidden cancers
Diagnosis Recruiting nowThis study is testing a new type of PET scan that targets a protein called DLL3, found on some neuroendocrine cancer cells. The goal is to see if this scan can find tumors more accurately than current imaging methods. About 60 adults with suspected or confirmed neuroendocrine can…
Matched conditions: DLL3-EXPRESSING TUMORS
Phase: NA • Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Diagnosis
Last updated Jun 27, 2026 11:00 UTC